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CC BY-NC-ND license (http://creativeBackground: Human metapneumovirus (HMPV) is a recently discovered respiratory pathogen of
the family Paramyxoviridae, the same family as that of respiratory syncytial virus (RSV). Pre-
mature children are at high risk of severe RSV infections, however, it is unclear whether HMPV
infection is more severe in hospitalized children with a history of severe prematurity.
Methods: We conducted a retrospective analysis of the clinical respiratory presentation of all
polymerase chain reaction-confirmed HMPV infections in preschool-age children (5 years)
with and without history of severe prematurity (<32 weeks gestation). Respiratory distress
scores were developed to examine the clinical severity of HMPV infections. Demographic
and clinical variables were obtained from reviewing electronic medical records.
Results: A total of 571 preschool children were identified using polymerase chain reaction-
confirmed viral respiratory tract infection during the study period. HMPV was identified as a
causative organism in 63 cases (11%). Fiftyeeight (n Z 58) preschool-age children with HMPVPediatric Pulmonology and Sleep Medicine, Children’s National Medical Center, Center for Genetic
ue, NW, Washington, DC 20010, USA.
tional.org (G. Nino).
015.03.008
Pediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
28 K. Pancham et alinfection were included in this study after excluding those with significant comorbidities. Our
data demonstrated that 32.7% of children admitted with HMPV had a history of severe prema-
turity. Preschool children with a history of prematurity had more severe HMPV disease as illus-
trated by longer hospitalizations, new or increased need for supplemental O2, and higher
severity scores independently of age, ethnicity, and history of asthma.
Conclusion: Our study suggests that HMPV infection causes significant disease burden among
preschool children with a history of prematurity leading to severe respiratory infections and
increasing health care resource utilization due to prolonged hospitalizations.
Copyright ª 2016, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
Respiratory tract infections are the second leading cause of
death among children who are aged < 5 years worldwide.1
Human metapneumovirus (HMPV), a relatively new respi-
ratory pathogen of the family Paramyxoviridaedthe same
family as that of respiratory syncytial virus (RSV)dwas
discovered only a decade ago,2 however, it is now recog-
nized as a frequent cause of acute lower respiratory tract
infections in the pediatric population.1,4e6 Most children
who are <5 years old have already been infected with
HMPV,3 with the overall prevalence of acute HMPV infection
in the pediatric population ranging from 5e25% with some
variation across different regions and age groups.5,7e12 It
has been estimated that approximately 27,000 HMPV-
related hospitalizations will occur per year in the future
among preschool children in the US.13 This estimation is
alarming and emphasizes the need to investigate the
epidemiology and pathogenesis of HMPV in children.
HMPV shares the same clinical respiratory signs and
symptoms as RSV, including cough, wheezing, rales, hyp-
oxemia, and respiratory distress in high-risk groups.5,14e16
HMPV lower respiratory tract infections contribute to
5e15% of all hospitalizations in infants and young chil-
dren.17,18 Despite the importance of this pathogen in the
pediatric population, no treatment or prevention strategies
have been developed,19,20 which may reflect the lack of
understanding of the risk factors that increase the
morbidity and mortality of HMPV infection in children.19,20
Interestingly, prematurity has recently been suggested to
be an important risk factor for severe HMPV infection.20e22
Young children with a history of prematurity are at an
increased risk of hospitalization and frequent outpatient
visits due to HMPV bronchiolitis and pneumonia,20e23 epi-
demiologies that resemble the phylogenetically and clini-
cally related pathogen RSV.21 Other risk factors associated
with severe HMPV infection include immunosuppression,
young age, and existence of underlying comorbidities, such
as asthma, congenital heart diseases, neuromuscular dis-
orders, and other chronic pulmonary conditions.23e25
Although the aforementioned risk factors have been
reported, there are limited data about the clinical pre-
sentation of severe HMPV infection in hospitalized prema-
ture children. Moreover, the link between the severity of
HMPV respiratory infections and the history of prematurity
in hospitalized children still needs to be better defined.Accordingly, the aim of this cross-sectional study was to
examine the clinical severity of HMPV infection in hospi-
talized children aged  5 years with and without a history
of severe prematurity (<32 weeks gestation), using respi-
ratory parameters derived from standardized bronchiolitis
scores validated by our group,26,27 and health care utiliza-
tion (i.e, length of admission).
2. Materials and methods
2.1. Study participants
We conducted a retrospective cross-sectional analysis of a
cohort of preschool children aged  5 years who were
admitted with HMPV infection, which was confirmed using
polymerase chain reaction (PCR) analysis, at Children’s
National Medical Center (CNMC) between January 2013 and
February 2014. Viral PCRs were performed on patients who
presented to the hospital with suspected viral respiratory
tract infection at the discretion of the clinician. We only
included children with positive PCR for HMPV and excluded
individuals with mixed viral infections.
Patients with significant comorbidities such as cardio-
respiratory conditions (other than asthma and prematu-
rity), genetic syndromes, and immunosuppression were
excluded from the study. This study was approved by the
Institutional Review Board at CNMC.
2.2. Clinical and demographic variables
Clinical and demographic variables were obtained by
reviewing electronic medical records (EMR) at CNMC. De-
mographic variables comprised gestational age in weeks,
age, sex, and ethnicity. Other clinical variables included
tachypnea, retractions, abnormal breath sounds
(wheezing), asthma diagnosis, oxyhemoglobin saturation
values by pulse oximetry (SaO2), supplemental oxygen (O2)
requirement relative to the patient’s baseline, length of
hospitalization, and the need for admission to the pediatric
intensive care unit (PICU). In our institution, PICU admission
criteria include worsening hypoxemia or hypercapnia,
worsening respiratory distress, continuing requirement for
>50% O2, hemodynamic instability, and apnea. In addition,
in the setting of viral respiratory tract infection PICU
admission is also required for the following: (1) initiation of
Severe respiratory disease in preschool children 29“noninvasive advanced respiratory support”, which is
defined as the use of high-flow nasal cannula or positive
airway pressure via mask in continuous or bilevel modes;
and (2) initiation of mechanical ventilator support via
endotracheal intubation or tracheostomy. Patients with
baseline mechanical ventilator support are not automati-
cally admitted to PICU unless that there is a modification in
baseline parameters. The variable “need for invasive me-
chanical support” during HMPV infection was defined as
new onset of mechanical support, or increase in baseline
parameters from baseline.
For the purpose of the study, clinical parameters were
characterized as binary outcome for: severe prematurity
defined a priori by a gestational age of <32 weeks to
include extremely preterm and very preterm patients
based on the World Health Organization definition of pre-
maturity,28 asthma status, and O2 supplementation.
Tachypnea was stratified and scored in groups (0e3) ac-
cording to respiratory rate definitions used in bronchiolitis
scores as follows: 0 for <30 breaths/min (bpm); 1 for
30e45 bpm; 2 for 46e60 bpm; and 3 for >60 bpm.27,29
“Asthma” was defined in this pediatric population using a
definition that required the presence of at least one of the
following criteria: (1) ever being diagnosed with asthma by
a physician on the basis of criteria recommended for chil-
dren in the National Asthma Education and Prevention
Program Guidelines; and (2) use of asthma therapy and/or
presence of asthma symptoms in the past 12 months and
previously described.30Table 1 Baseline characteristics for study patients with
human metapneumovirus (HMPV). Comparison of children
with and without history of severe prematurity (<32 weeks
gestation) and comorbidities of premature patients. For
quantitative variables, data are presented as
mean  standard deviation (SD). For categorical variables,
data are presented as count number (column percentage).
The p values are obtained using either two-sample t test, or
Chi-square test, depending on the type of variables.




39  1.8 26.2  2.5 <0.001
Sex (Male) 23 (58) 9 (53) 0.676
Age (y) 2.1  1.6 1.9  1.6 0.549
Race/Ethnicity
e Black 23 (58) 8 (42) 0.221
e White 5 (13) 7 (37) 0.051
e Hispanic, 11 (28) 4 (21) 0.545




7 (37)2.3. Clinical evaluation of viral respiratory tract
infection severity based on lower airway
obstruction and respiratory distress
To retrospectively assess overall clinical severity of HMPV
infection, we recorded wheezing, retractions, supple-
mental O2 need (which we found retrospectively to be more
consistently documented than the exact initial SaO2 satu-
ration), and tachypnea at the initial presentation based on
EMR and combined them in a respiratory distress score
(0e10). For this score, we used a stratified value for
tachypnea (0e3) and combined assigned values with the
binary need of O2 (0e2), presence of wheezing (0e3), and
retractions (0e2), yielding a total maximal value of 10
points (Table S1). Of note, the four clinical variables
included in this respiratory distress score were selected
because they represented the main phenotypical features
of viral bronchiolitis in children, lower airway obstruction,
and respiratory distress,30 and they are the parameters
included in the bronchiolitis scores validated by our group











Data are presented as mean  SD or n (%).2.4. Statistical analysis
Data were analyzed using the software SAS version 9.3 (SAS
Institute Inc., Cary, NC, USA). Descriptive statistics were
used to calculate the prevalence of HMPV. Collected de-
mographic and clinical data were compared with the use of
a Chi-square test (categorical variables) or t test orWilcoxon rank-sum test, as appropriate for continuous
variables. Significance was taken at the p < 0.05 level.
3. Results
3.1. Prevalence of prematurity in hospitalized
preschool children with HMPV infection
We reviewed records of all preschool-age children (0e5
years) admitted to our institution during the 2013 season
with a PCR confirmed diagnosis of viral respiratory tract
infection (n Z 571). We identified HMPV as the causative
organism in 63 cases (11%). Fifty-eight (n Z 58) preschool-
age children with HMPV infection were included in this
study after excluding those with significant comorbidities
such as cardiorespiratory conditions (other than asthma and
prematurity). In terms of age distribution, a history of se-
vere prematurity (born at <32 weeks gestational age) was
present in 42% (nZ 8/19) in infants aged < 1 year and 24%
(n Z 9/39) of individuals aged 1e5 years. The overall
prevalence of a history of severe prematurity was 32.7% in
the entire population (n Z 19/58), indicating that prema-
turity was highly prevalent in preschool children hospital-
ized due to HMPV infection. Clinical characteristics and
comorbidities of premature children with HMPV infection
are shown in Table 1. Comparison of demographic and
Table 2 Clinical severity parameters in children with
human metapneumovirus (HMPV) infection. Comparison of
children with and without history of severe prematurity. For
quantitative variables, data are presented as
mean  standard deviation (SD). For categorical variables,
data are presented as count number (column percentage).
The p values are obtained using either two-sample t test, or
Chi-square test, depending on the type of variables.
Nonpremature Premature p
N 39 19
Initial O2 saturation (%) 95  3.4 89  7.1 <0.01
Mean total respiratory
distress score (0e10)




15 (38.4) 16 (84) <0.01
e Stratified
tachypnea (0e3)
1.21  0.9 1.73  0.7 0.04
e Wheezing 22 (56.4) 15 (79) 0.09
e Subcostal retractions 20 (51.2) 15 (79) 0.04
Date are presented as mean  SD or n (%).
30 K. Pancham et albaseline study variables of children with and without a
history of severe prematurity revealed no significant dif-
ferences (Table 1).
3.2. HMPV in premature children is associated with
higher clinical severity
To assess HMPV severity in premature children, we first
evaluated the absolute degree of hypoxemia assessed with
the value of SaO2 at presentation, which was significantly
lower in children with history of severe prematurity [mean
SaO2 89%; 95% confidence interval (CI) Z 85.5e94.1%]
relative to children born at term (mean SaO2 95%; 95%
CIZ 94.4e96.7%). We also investigated the odds of needing
supplemental O2 (new or increased from baseline) in
severely premature children hospitalized with HMPV
infection. After adjusting for age, sex, and history ofFigure 1 Comparative chest radiographs (CXRs) of a 2-year-old p
(A) Initial CXR during admission to the hospital due to HMPV infecti
48 hours later CXR shows progression of right lower lung opacitie
entry, respiratory distress, and hypoxemia.asthma (logistic regression), we identified that severely
premature children were six times more likely to need
supplemental O2 [adjusted odds ratio (OR) 5.9; 95%
CI Z 1.25e26.; p Z 0.02]. We next examined the overall
clinical severity using a respiratory distress score (0e10;
Table S1), which includes the most characteristic pheno-
typical features of viral bronchiolitis: lower airway
obstruction (wheezing) and respiratory distress (subcostal
retractions, supplemental O2 need, and tachypnea).
26,27
Severely premature born children with HMPV had more
severe respiratory distress scores relative to nonpremature
HMPV-infected children [score mean  standard deviation
(SD) in full term HMPV-infected 4.7  3.3 and in severely
premature HMPV-infected 7.3  2.3, p < 0.01; Table 2].
Individual parameters of respiratory distress were also
significantly increased except for wheezing that did not
reach statistical significance (Table 2).
In terms of the clinical presentation of premature chil-
dren infected with HMPV, we found that lung auscultation
and chest radiographs were abnormal in virtually all cases.
Specifically, diffuse or localized crackles were present in
95% of the cases (n Z 18/19) and focal infiltrates were
identified in 74% (n Z 14/19) of premature born children
infected with HMPV. Lung infiltrates in premature born
children infected with HMPV were typically poorly defined
air occupying lesions affecting different segments of both
lungs (Figure 1). These focal infiltrates were not associated
with ground-glass pattern, pleural effusion, or necrotizing
pneumonia in any of the cases. Fever (>38 C) was present
in 68% of the cases (nZ 13/19), however, it was typically a
low degree and present only during the onset of the
symptoms. In terms of laboratory abnormalities,
mildemoderate leukocytosis was identified in 26% of the
cases (nZ 5/19) and mild thrombocytopenia was present in
two of the premature children infected with HMPV.
3.3. Severe prematurity is associated with longer
hospitalization in children with HMPV infection
Preschool children with HMPV infection had a median
duration of hospitalization of 4 days (95% CI 2.6e4.7 days,remature girl with human metapneumovirus (HMPV) infection.
on showing a focal infiltrate in the right lower lobe (arrow); (B)
s (arrow) that correlated with worsening of crackles, poor air
Severe respiratory disease in preschool children 31Figure 2). By contrast, preschool children with a history of
severe prematurity had a significantly longer hospitaliza-
tion during HMPV infection with a median of 9 days (95% CI
6.8e12.7 days, Figure 2). Interestingly, the length of hos-
pitalization during HMPV infection was nonsignificantly
different in preschool children with the diagnosis of asthma
relative to that in individuals without history of this con-
dition (nonasthmatic children median 3.2 days, 95% CI
2.2e6.3 vs. asthmatic children median 4.7 days, 95% CI
4.1e6.4; p > 0.05). During the study period, 23 children
with HMPV infection were admitted to PICU (39%). Thir-
tyethree percent of nonpremature children with HMPV
infection needed PICU admission (nZ 13/39). In the group
of severely premature children, 58% were admitted to PICU
(n Z 11/19). Premature born children hospitalized with
HMPV infection were more likely to require noninvasive
respiratory support (n Z 5/39 nonpremature vs. n Z 7/19
premature; p < 0.05). No significant differences were found
in the need for invasive mechanical ventilation (n Z 5/39
nonpremature vs. n Z 5/19 premature; p Z 0.07), and no












Figure 2 Mean duration of hospitalization in children with
HMPV infection. Bars represent the 95% confidence interval for
the median length of admission (hospital days) in children with
and without history of (A) severe prematurity or (B) asthma.
The p values were obtained using nonparametric Mann-Whitney
test contrasting median hospital days in the two groups
presented.4. Discussion
Our data demonstrated that hospitalized preschool children
(aged  5 years) with HMPV and history of severe prema-
turity (born 32 weeks gestational age) had severe HMPV
disease, illustrated by high clinical severity scores
(wheezing, retractions, need for supplemental O2, and
tachypnea) relative to children without history of prema-
turity. We also identified that severe prematurity was
associated with a twofold increase in the duration of HMPV
hospitalization in preschool-aged children. Accordingly, this
study provides new evidence to support that severe pre-
maturity is an important risk factor to be considered in the
development of preventive strategies to reduce morbidity,
mortality, and high costs generated by HMPV infection
during the first years of life.
HMPV and RSV infection have similar clinical respiratory
signs and symptoms, including cough, wheezing, rales,
hypoxemia, and respiratory distress in the same high-risk
groups.5,14e16 Premature children are at increased risk of
severe RSV infections that can lead to hospitalization, PICU
admission, and death.25 The clinical features of lower res-
piratory tract infection and the disease spectrum caused by
HMPV and RSV are quite similar, with similar possible risk
factors. In this study, a focus on prematurity’s association
with the severity of HMPV has been established. Our results
revealed that premature children aged 0e5 years acquired
a more clinically severe HMPV infection than children who
were born nonpremature. In agreement with our observa-
tions, a study by Papenburg et al21 identified that prema-
turity was more frequent among HMPV hospitalized children
who were aged 0e5 months compared with nonpremature
children who presented to the pediatric clinic. Similar to
our present results, their severity score was based on the
inclusion of at least one of the following criteria: admission
to PICU, hospitalization stay > 5 days, and a requirement
for supplemental O2. Moreover, prematurity was indepen-
dently associated with increased severity of HMPV infection
among hospitalized children of the same cohort (OR, 13.97;
95% CI, 1.5e130).21 Population-based studies have identi-
fied that HMPV can cause severe respiratory compromise in
premature infants and children with or without chronic lung
disease.32 In another investigation by Robinson et al33 34%
of HMPV hospitalized children were born premature, sug-
gesting that prematurity could be as important risk factor
as it is for RSV, however, the severity of HMPV infection in
premature children was not quantified. In our study we
modified bronchiolitis severity scores validated in hospi-
talized children27,29 to allow the retrospective assessment
of the most characteristic phenotypical features of viral
bronchiolitis: lower airway obstruction (wheezing) and
respiratory distress (subcostal retractions, need for sup-
plemental O2, and tachypnea).
26,27 Given that EMR review
did not allow us to assign mild/severe categories for
wheezing and retractions accurately, we used binary vari-
ables with weighted scores and combined with hypoxemia
and stratified tachypnea (0e3). Using this approach we
were able to determine that children with history of severe
prematurity develop more hypoxemia, stratified tachyp-
nea, and subcostal retractions during HMPV infection.
Wheezing alone was not more common in children with
32 K. Pancham et alhistory of prematurity, suggesting that rather than trig-
gering airway reactivity, HMPV primarily exacerbates
abnormal alveolar gas/exchange in the lungs of young
children with history of severe prematurity. This is further
supported by the presence of crackles and alveolar in-
filtrates in most of the premature children infected with
HMPV (Figure 1).
We also investigated whether the severe HMPV infection
in premature children may impact health care resource
utilization in preschool children hospitalized with HMPV
infection. To this end, we contrasted the length of hospi-
talization (days) in patients with and without a history of
severe prematurity. Our results showed that the mean
duration of hospitalization in infants with severe prema-
turity was two times higher (9 days vs. 4 days; p < 0.05, see
Figure 2). By comparison, asthmatic children with HMPV did
not have longer hospitalizations than nonasthmatic chil-
dren. This indicates that additional factors (other than
airway hyperreactivity/asthma) are present in children
with a history of severe prematurity that make them more
susceptible to respiratory viruses in early life. Based on our
data reporting that hypoxemia is a common clinical pre-
sentation of HMPV in this population, it is possible that
prematurity predisposes patients to more alveolar damage
during HMPV infection. In parallel with longer hospitaliza-
tion and frequent need for supplemental O2, we also
identified that children with a history of severe prematurity
often required advanced respiratory support, which in our
institution includes the use of high-flow nasal cannula or
positive airway pressure via mask in continuous or bilevel
modes in the PICU. Collectively, our data indicate that
HMPV infection in children with history of prematurity is
associated with severe respiratory disease and consequent
increase in health care utilization.
Our findings add more support to the prevalent notion
that the length and costs of hospitalizations in severely
preterm infants are very high,34,35 with the cost being
inversely proportional to decreasing gestational age, and
birth weight.34,35 This is further aggravated by the fact that
premature infants are at high-risk of recurrent hospitali-
zation due to lower respiratory tract infections, as well as
chronic pulmonary symptoms.36 Moreover, although
severely premature children have a high incidence of hos-
pitalizations in the first few years of life,37,38 there is also
evidence than these children need more respiratory health
care services later in childhood.37,38 This may in part be due
to other comorbidities associated with prematurity such as
neurological impairment, artificial airways, and respiratory
support that result in high care resource utilization at least
during the first 5-years of life.31 Accordingly, our current
data demonstrates that there is an association between
prematurity and severe HMPV infection during the first 5-
years of life, and thus provides additional support for the
potential use of preventive measures for HMPV infected
children with a history of prematurity to ameliorate
morbidity and mortality in this vulnerable population
through childhood. Some future preventive strategies
against HMPV may include the use of passive prophylaxis
because it has been implemented with a F protein-directed
monoclonal antibody (mAb)epalivizumab against RSV.
However, it is important to mention that mAb prophylaxis-
based approaches have pros and cons. For instance, whilepalivizumab was initially shown to reduce RSV-associated
hospitalization by 39e78% in selected high-risk premature
infants,39 subsequent cost-economic analyses of pal-
ivizumab prophylaxis indicated that it did not represent
good value for money when used unselectively in chil-
dren.40 However, subgroup analysis suggests that prophy-
laxis with palivizumab may be cost-effective for some
subgroups, particularly those with chronic lung disease of
prematurity or congential heart disease (higherisk
groups).40 In addition to risk stratification, we also believe
that clinicians should consider local socioeconomic factors
to determine whether mAb-based prophylaxis approaches
are cost-effective in their clinical setting and geographic
area.
The main limitations of the present study are its retro-
spective design, the small sample size, the limited number
of predictor variables included in the multivariate analysis,
and the fact that it was conducted in a specialized, tertiary
referral hospital. With respect to the first point, because
the data were taken from EMR, and the majority of vari-
ables analyzed were hard variables, it is unlikely that its
retrospective design significantly compromised the validity
of data collected. Secondly, although our statistical anal-
ysis included a small number of patients and limited pre-
dictor variables, we obtained an adequate signal
(significant results) after including the majority of variables
that have been reported in literature as validated markers
of bronchiolitis severity and potential confounders.26,27
However, as is the case in cross-sectional studies, residual
confounding and type II error (due to a small sample size)
cannot be excluded, therefore, interpretation of our results
requires caution. It is also important to mention that
important variables could not be obtained in our EMR re-
view, including insurance information, the duration be-
tween symptom onset, and hospitalization as well as
specific medical treatment(s) provided. Our study patients
underwent viral PCR analysis at the discretion of the clini-
cian, which can result in selection bias. Lastly, it is
important to emphasize the fact that the study was con-
ducted in a specialized, tertiary referral hospital makes it
likely that the patients included represent the extreme of
the spectrum of severity of all patients with HMPV infec-
tion, which could limit the generalization of results to other
contexts (external validity). However, the similarity of the
results to previous studies linking prematurity with
HMPV,20e22 as well as with the phylogenetically and clini-
cally related pathogen RSV,2 suggests that the results of this
study could be extrapolated to other contexts.
In summary, our data demonstrated that preschool
children with a history of prematurity had the more severe
cases of HMPV disease, according to clinical scoring of
wheezing, retractions, need for supplemental O2, and
tachypnea. Importantly, greater clinical severity also
translated into increased health care resource utilization
with a twofold increase in the duration of hospitalization
relative to individuals with HMPV infection and no history of
prematurity.Conflicts of interest
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